Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic

References

• Shen C. Incidence and prevalence of neuroendocrine tumors in the United States 1973-2012. Poster session presented at: North American Neuroendocrine Tumor Society (NANETS) Annual Symposium; 2016 Sep 30; Jackson Hole, WY
   Google Scholar
• Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72
   PubMed Web of Science ®Google Scholar
• Barakat M, Meeran K, Bloom S. Neuroendocrine tumours. Endocr Relat Cancer 2004;11:1-18
   PubMed Web of Science ®Google Scholar
• Modlin IM, Moss SF, Oberg K, et al. Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aust 2010;193:46-52
   PubMed Web of Science ®Google Scholar
• Strosberg J, Casciano R, Stern L, et al. United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment. World J Gastroenterol 2013;19:2348
   PubMed Web of Science ®Google Scholar
• Chuang C-C, Bhurke S, Chen S-Y, et al. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study. J Med Econ 2015;18:126-36
   PubMed Web of Science ®Google Scholar
• Afinitor (everolimus) tablets for oral administration [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp, 2016
   Google Scholar
• Somatuline Depot (lanreotide) injection [prescribing information]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc., 2014
   Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Neuroendocrine Tumors V.2.2016. National Comprehensive Cancer Network, Inc., 2016. All rights reserved. Accessed May 27, 2016. To view the most recent and complete version of the guideline, go to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 2016
   Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Small Cell Lung Cancer V.1.2016. National Comprehensive Cancer Network, Inc., 2016. All rights reserved. Accessed June 30, 2016. To view the most recent and complete version of the guideline, go to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 2016
   Google Scholar
• Bureau of Labor Statistics. Washington, DC: US Department of Labor. Consumer Price Index (CPI), 2016. http://www.bls.gov/cpi/. Accessed March 24, 2016
   Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17:5-14
   PubMed Web of Science ®Google Scholar
• Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25,531). Ann Oncol 2013;24:3040-4
   PubMed Web of Science ®Google Scholar
• Chong C, Wirth L, Nishino M, et al. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer 2014;86:241-6
   PubMed Web of Science ®Google Scholar
• Choti MA, Bobiak S, Strosberg JR, et al. Prevalence of functional tumors in neuroendocrine carcinoma: an analysis from the NCCN NET database. J Clin Oncol 2012;30:(Suppl; abstr 4126)
   Google Scholar
• Gustafsson B, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:5-21
   PubMed Web of Science ®Google Scholar
• Yalchin M, Garcia-Hernandez J, Mullan M, et al. Epidemiological characteristics from a single centre database cohort of 1301 neuroendocrine tumour patients: is there an association between age and grade of NET? Gasteroentrology 2015;148:S-936
   Google Scholar
• Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005;23:4897-904
   PubMed Web of Science ®Google Scholar
• Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007;59:637-42
   PubMed Web of Science ®Google Scholar
• Afinitor (everolimus) NET forecast. East Hanover, NJ: Novartis Pharmaceuticals Corp (data on file). 2016
   Google Scholar
• RedBook ReadyPrice Online®. Ann Arbor, MI: Truven Health Analytics Inc., 2016. http://www.micromedexsolutions.com/micromedex2/librarian/. Accessed April 19, 2016
   Google Scholar
• Ramsey S, Shankaran V. Managing the financial impact of cancer treatment: the role of clinical practice guidelines. J Natl Compr Canc Netw 2012;10:1037-42
   PubMed Web of Science ®Google Scholar
• Moertel CG, Kvols LK, O’Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 1991;68:227-32
   PubMed Web of Science ®Google Scholar
• Sutent (sunitinib malate) capsules, oral [prescribing information]. New York, NY: Pfizer, Inc., 2015
   Google Scholar
• Sandostatin LAR Depot (octreotide) injection [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp, 2014
   Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-12
   PubMed Web of Science ®Google Scholar
• PROMID Clinical Study Report. East Hanover, NJ: Novartis Pharmaceuticals Corp (data on file). 2009
   Google Scholar
• Hagiwara M, Hackshaw MD, Oster G. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma. J Med Econ 2013;16:1300-6
   PubMedGoogle Scholar
• Burudpakdee C, Zhao Z, Munakata J, et al. Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies. J Med Econ 2012;15:371-7
   PubMedGoogle Scholar
• Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008;26:606-11
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Kartashov A, et al. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. Chemotherapy 2012;58:8-18
   PubMed Web of Science ®Google Scholar
• National Physician Fee Schedule. Baltimore, MD: Center for Medicare and Medicaid Services (CMS), 2015. https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. Accessed April 19, 2016
   Google Scholar
• Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Supportive Care Cancer 2011;19:131-40
   PubMed Web of Science ®Google Scholar
• Pike CT, Birnbaum HG, Muehlenbein CE, et al. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:1-10
   Google Scholar
• Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality, 2012. http://hcupnet.ahrq.gov/. Accessed April 19, 2016
   Google Scholar
• MAG Mutual Healthcare Solutions. Physicians Fee & Coding Guide. Atlanta, GA: MAG Mutual Healthcare Solutions, Inc.; 2012
   Google Scholar
• Dasari A. Changing trends in the epidemiology and survival of neuroendocrine tumors in the United States: a SEER population-based study of 64,971 cases. Poster session presented at: North American Neuroendocrine Tumor Society (NANETS) Annual Symposium; 2016 Sep 30; Jackson Hole, WY
   Google Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72
   PubMed Web of Science ®Google Scholar
• Wolin EM. Challenges in the diagnosis and management of well-differentiated neuroendocrine tumors of the lung (typical and atypical carcinoid): current status and future considerations. Oncologist 2015;20:1123-31
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-91
   PubMed Web of Science ®Google Scholar
• Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 2013;71:663-70
   PubMed Web of Science ®Google Scholar